We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Halaven Wins FDA Approval as Third-Line Breast Cancer Treatment
Halaven Wins FDA Approval as Third-Line Breast Cancer Treatment
November 19, 2010
More than a month before its user fee action date, the FDA has approved Eisai’s late-stage breast cancer treatment Halaven.